No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding in July 2021, maintains a robust pipeline of therapeutic candidates. This includes GND-004, designed for both ophthalmic conditions and oncology, and GND-007, aimed at immunological disorders. Their portfolio also features a range of antibodies being developed for cancer therapies. Further expanding its research, the GBS series encompasses GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for eye-related ailments; GBS-008 for infectious diseases; and GBS-011 for renal conditions. Additionally, Kidswell Bio is progressing GCT-101 for alveolar clefts, GCT-102 for congenital isolated hypoganglionosis, alongside other investigational products addressing ophthalmologic disorders, cerebral palsy, peripheral nerve palsy, fractures, and spinal cord injuries.
www.kidswellbio.comNo one on the platform currently holds 4584.T.
No tracked institution reports a position in 4584.T as of their last filing.
No one on the platform has traded 4584.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 29.7% | 45.9% | ||||
| Profit Margin % | -6.3% | -24.8% | ||||
| Free Cash Flow Margin % | -16.9% | -28.6% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $4.9B | +14.3% | $19.30 | $19.30–$19.30 | — | 1 |
| 2028 | $5.6B | +14.0% | $29.60 | $29.60–$29.60 | — | 1 |
| 2029 | $5.8B | +4.0% | $32.70 | $32.70–$32.70 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4584.TKidswell Bio Corporation | $165.00 | +0.00% | $8.2B | — |
| 2370.TMEDINET Co., Ltd. | $24.00 | +0.00% | $6.7B | — |
| 2689.TOLBA HEALTHCARE HOLDINGS, Inc. | $1926.00 | -1.88% | $11.4B | — |
| 4571.TNANO MRNA Co.,Ltd. | $98.00 | -2.97% | $8.2B | — |
| 4579.TRaQualia Pharma Inc. | $568.00 | +1.43% | $13.9B | — |
| 4583.TChiome Bioscience Inc. | $88.00 | +1.15% | $6.4B | — |
| 4875.TMediciNova, Inc. | $305.00 | +4.81% | $15.0B | — |
Source: Financial Modeling Prep · peers by sector/industry